Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA

BACKGROUND: Targeted therapies (TKI) have improved the prognosis of ALK-rearranged lung cancer (ALK(+) NSCLC), but clinical courses vary widely. Early identification and molecular characterisation of treatment failure have key importance for subsequent therapies. We performed copy number variation (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EBioMedicine
Main Authors: Dietz, Steffen, Christopoulos, Petros, Yuan, Zhao, Angeles, Arlou Kristina, Gu, Lisa, Volckmar, Anna-Lena, Ogrodnik, Simon J., Janke, Florian, Fratte, Chiara Dalle, Zemojtel, Tomasz, Schneider, Marc A., Kazdal, Daniel, Endris, Volker, Meister, Michael, Muley, Thomas, Cecchin, Erika, Reck, Martin, Schlesner, Matthias, Thomas, Michael, Stenzinger, Albrecht, Sültmann, Holger
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2020
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7670098/
https://ncbi.nlm.nih.gov/pubmed/33161228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.103103
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados